







| 货号 | HB011036 |
|---|---|
| 品牌 | abinScience |
| 描述 |
Epratuzumab (HB011036) is a research-grade recombinant antibody targeting CD22. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 同种型 | IgG1-nd |
| 表达系统 | Mammalian cells |
| 经测试应用 | FCM |
| 靶标 | Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22 |
| 内毒素水平 | < 10 EU/mg |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | P20273 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | 90Y-DOTA-hLL2, 90Y-epratuzumabtetraxetan, AMG-412, 90Y-hLL2, hLL2, 205923-57-5 |
| 背景 | B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SDS-PAGE for Research Grade Epratuzumab.

Flow-cytometry using APC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD22 monoclonal antibody (Catalog HB011036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using PE anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD22 monoclonal antibody (Catalog HB011036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using FITC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD22 monoclonal antibody (Catalog HB011036, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.









24小时产品查询

扫一扫关注我们

专属渠道经理